Molgramostim Inhalation Solution

Name: Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Humanistic burden and health-related quality of life
Published: 2026-09-14T15:39:06-04:00

Autoimmune pulmonary alveolar proteinosis

Manufacturer: Savara
Regulatory submission: BLA resubmitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Autoimmune pulmonary alveolar proteinosis

Humanistic burden and health-related quality of life

1 evidence topic · 3 sources

Reported burden of current treatments and off-label therapies

“burdensome, emotionally taxing, and/or financially worrisome.” (opens the source at this quote in a new tab)